On the stock market since 2014, it operates in the world of health and science. It has 121 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 8% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 53% below its peak. The market has trimmed its expectations for the company.
There is $53.1M in the vault; even if every debt were paid off, $45.0M would remain.
Over the last 12 months, company executives reported 6 buys and 0 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $26.00 — 97% above today’s price.
A loss of $23.9M against $17.0M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 2.2 years. After that, the company needs to find new money.
On our five-subject report card, MDWD sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MDWD is a small company that closed last year at a loss. The road back to profit runs through spending discipline.